The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Blocking the apolipoprotein E/amyloid-β interaction as a potential therapeutic approach for Alzheimer's disease
Open accessAbstract
The amyloid-β (Aβ) cascade hypothesis of Alzheimer's disease (AD) maintains that accumulation of Aβ peptide constitutes a critical event in the early disease pathogenesis. The direct binding between Aβ and apolipoprotein E (apoE) is an important factor implicated in both Aβ clearance and its deposition in the brain's parenchyma and the walls of meningoencephalic vessels as cerebral amyloid angiopathy. With the aim of testing the effect of blocking the apoE/Aβ interaction in vivo as a potential novel therapeutic target for AD pharmacotherapy, we have developed Aβ12-28P, which is a blood-brain-barrier-permeable nontoxic, and nonfibrillogenic synthetic peptide homologous to the apoE binding site on the full-length Aβ. Aβ12-28P binds with high affinity to apoE, preventing its binding to Aβ, but has no direct effect on Aβ aggregation. Aβ12-28P shows a strong pharmacological effect in vivo . Its systemic administration resulted in a significant reduction of Aβ plaques and cerebral amyloid angiopathy burden and a reduction of the total brain level of Aβ in two AD transgenic mice models. The treatment did not affect the levels of soluble Aβ fraction or Aβ oligomers, indicating that inhibition of the apoE/Aβ interaction in vivo has a net effect of increasing Aβ clearance over deposition and at the same time does not create conditions favoring formation of toxic oligomers. Furthermore, behavioral studies demonstrated that treatment with Aβ12-28P prevents a memory deficit in transgenic animals. These findings provide evidence of another therapeutic approach for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We have used Ab12-28P in the past to successfully reduce Ab plaques load and CAA in APP SW and APP SW /PS1 M146L AD model mice.22”
From Blocking the Interaction between Apolipoprotein E and Aβ Reduces Intraneuronal Accumulation of Aβ and Inhibits Synaptic Degeneration (2013) · cites this paper as [22]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“One study found that antagonizing the apoE/Aβ interaction with a small peptide decreased Aβ pathology in the mouse brain”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [57]
The cited source says what the claim attributes to it.
In the citing paper
“A similar strategy preventing the interaction between apoE and Aβ has already been successfully used to attenuate Aβ toxicity and amyloid deposition (Sadowski et al., 2006).”
From Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aβ amyloidosis (2012) · cites this paper as Sadowski et al., 2006
The cited source says what the claim attributes to it.
In the citing paper
“Aβ12-28P inhibits apoE4/Aβ binding with KI = 12.9 nM and neutralizes the promoting effect of apoE on Aβ fibrillization in vitro, but has no effect on self-assembly of Aβ in the absence of apoE [15].”
From Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice (2014) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“Consistently with our previously published observations [15] these results indicate that Aβ12-28P exerts an effect on serum cholesterol metabolism in addition to targeting the apoE/Aβ interaction in the brain.”
From Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice (2014) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“There is compelling evidence showing that apoE affects A accumulation by modulating both A aggregation (Ma et al., 1994;Wisniewski et al., 1994) and clearance (Sadowski et al., 2006;Deane et al., 2008;Jiang et al., 2008;Castellano et al., 2011)”
From Anti-ApoE Antibody Given after Plaque Onset Decreases Aβ Accumulation and Improves Brain Function in a Mouse Model of Aβ Amyloidosis (2014) · cites this paper as Sadowski et al., 2006
The cited source says what the claim attributes to it.
In the citing paper
“Conversely, blocking the interaction between apoE and A (Sadowski et al., 2006) and decreasing the apoE level by overexpressing low-density lipoprotein receptor (Kim et al., 2009) or haploinsufficiency of apoE (Bales et al., 1999;Holtzman et al., 2000;Kim et al., 2011;Bien-Ly et al., 2012) results in decreased amyloidosis.”
From Anti-ApoE Antibody Given after Plaque Onset Decreases Aβ Accumulation and Improves Brain Function in a Mouse Model of Aβ Amyloidosis (2014) · cites this paper as Sadowski et al., 2006
The cited source says what the claim attributes to it.
In the citing paper
“As we have previously shown, Ab12-28P inhibits ApoE4/Ab binding with K I Z 12.9 nmol/L, neutralizes the promoting effect of ApoE on Ab fibrillization in vitro, and reduces the load of Ab plaques and CAA when systemically administered to APP SW Tg mice.22”
From Blocking the Interaction between Apolipoprotein E and Aβ Reduces Intraneuronal Accumulation of Aβ and Inhibits Synaptic Degeneration (2013) · cites this paper as [22]
The cited source says what the claim attributes to it.
In the citing paper
“As we have previously shown, Ab12-28P inhibits ApoE4/Ab binding with K I Z 12.9 nmol/L, neutralizes the promoting effect of ApoE on Ab fibrillization in vitro, and reduces the load of Ab plaques and CAA when systemically administered to APP SW Tg mice.22”
From Blocking the Interaction between Apolipoprotein E and Aβ Reduces Intraneuronal Accumulation of Aβ and Inhibits Synaptic Degeneration (2013) · cites this paper as [22]
The cited source says what the claim attributes to it.
In the citing paper
“As we have previously shown, Ab12-28P inhibits ApoE4/Ab binding with K I Z 12.9 nmol/L, neutralizes the promoting effect of ApoE on Ab fibrillization in vitro, and reduces the load of Ab plaques and CAA when systemically administered to APP SW Tg mice.22”
From Blocking the Interaction between Apolipoprotein E and Aβ Reduces Intraneuronal Accumulation of Aβ and Inhibits Synaptic Degeneration (2013) · cites this paper as [22]
The cited source says what the claim attributes to it.
In the citing paper
“As apoE co-deposits with Aβ in the amyloid plaques (13–15), we examined and found that the degree of co-localization between apoE and Aβ deposition appeared to decrease in the brains carrying APOE3-Jac variant compared to those from APOE3 (Fig. S1C–F).”
From APOE3 -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia (2021) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413
Gong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., Krafft, G. A., & Klein, W. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1834302100 · Cited by 1,061
Holtzman, D. M., Bales, K. R., Tenkova, T., Fagan, A. M., Parsadanian, M., Sartorius, L. J., Mackey, B., Olney, J., McKeel, D., Wozniak, D., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.050004797 · Cited by 937
Ma, J., Yee, A., Brewer, H. B., Das, S., & Potter, H. (1994) · Nature · doi:10.1038/372092a0 · Cited by 871
Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition
Bales, K. R., Verina, T., Dodel, R. C., Du, Y., Altstiel, L., Bender, M., Hyslop, P., Johnstone, E. M., Little, S. P., Cummins, D. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1197-263 · Cited by 830
Research works printed but not linked: 3
- 10.1172/JCI20337 · DOI
- T Wisniewski, EM Castaño, AA Golabek, T Vogel, B Frangione Am J Pathol 145, 1030–1035 (1994).
- SD Schmidt, Y Jiang, RA Nixon, PM Mathews Methods Mol Biol 299, 267–278 (2005).
Cited by
Sorted by citations
Items 101–166 of 166
Impact of Age on the Cerebrovascular Proteomes of Wild-Type and Tg-SwDI Mice
Searcy, J. L., Bihan, T. L., Salvadores, N., McCulloch, J., & Horsburgh, K. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089970 · Cited by 24
Raft aggregation with specific receptor recruitment is required for microglial phagocytosis of Aβ42
Persaud‐Sawin, D., Banach, L., & Harry, G. J. (2008) · Glia · doi:10.1002/glia.20759 · Cited by 24
ApoE: In Vitro Studies of a Small Molecule Effector
Mondal, T., Wang, H., DeKoster, G. T., Baban, B. A., Gross, M. L., & Frieden, C. (2016) · Biochemistry · doi:10.1021/acs.biochem.6b00324 · Cited by 25
Zhuang, T.-T., Pan, C., Chen, J., Han, F., Zhu, X.-L., Xu, H., & Lu, Y.-P. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.09.006 · Cited by 24
Křı́ž, Z., Klusák, J., Krištofíková, Z., & Koča, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062914 · Cited by 23
Park, S., & Kwon, Y.-U. (2015) · ACS Combinatorial Science · doi:10.1021/co5001647 · Cited by 22
Apolipoprotein E in Alzheimer’s Disease: Focus on Synaptic Function and Therapeutic Strategy
Qu, L., Xu, S., Lan, Z., Fang, S., Xu, Y., & Zhu, X. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04449-1 · Cited by 22
Future horizons in Alzheimer's disease research
Wısnıewskı, T., & Drummond, E. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.08.001 · Cited by 20
Hu, H., Wan, S., Hu, Y., Wang, Q., Li, H., & Zhang, N. (2025) · Annals of Medicine · doi:10.1080/07853890.2024.2445194 · Cited by 20
Goyal, M., Grover, S., Dhanjal, J. K., Goyal, S., Tyagi, C., Chacko, S., & Grover, A. (2013) · BioMed Research International · doi:10.1155/2013/620793 · Cited by 19
Han, F., Xu, H., Shen, J.-X., Pan, C., Yu, Z.-H., Chen, J.-J., Zhu, X.-L., Cai, Y.-F., & Lu, Y.-P. (2020) · Acta Neurobiologiae Experimentalis · doi:10.21307/ane-2020-021 · Cited by 18
Are the Effects ofAPOEɛ4 on Cognitive Function in Nonclinical Populations Age- and Gender-Dependent?
Rusted, J. M., & Carare, R. O. (2015) · Neurodegenerative Disease Management · doi:10.2217/nmt.14.43 · Cited by 18
Metal ion-dependent, reversible, protein filament formation by designed beta-roll polypeptides
Scotter, A. J., Guo, M., Tomczak, M. M., Daley, M. E., Campbell, R. L., Oko, R. J., Bateman, D. A., Chakrabartty, A., Sykes, B. D., & Davies, P. L. (2007) · BMC Structural Biology · doi:10.1186/1472-6807-7-63 · Cited by 18
Zhang, W., Li, Y., Nardi, M. A., Dang, S., Yang, J. L., Ji, Y., Li, Z., Karpatkin, S., & Wısnıewskı, T. (2010) · Blood · doi:10.1182/blood-2010-01-264358 · Cited by 17
Retracted: Advances in the physiological and pathological implications of cholesterol
Cortés, V., Busso, D., Mardones, P., Alberto Maiz, G., Arteaga, A., Nervi, F. O., & Rigotti, A. (2013) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12025 · Cited by 23
RetractedRaymond, S. B., Kumar, A. T. N., Boas, D. A., & Bacskai, B. J. (2009) · Physics in Medicine and Biology · doi:10.1088/0031-9155/54/20/011 · Cited by 16
Rodrigues, R., Smith, M. A., Wang, X., Perry, G. L., Lee, H., Zhu, X., & Petersen, R. B. (2012) · Future Neurology · doi:10.2217/fnl.12.27 · Cited by 14
Zhang, W., Du, Y., Bai, M., Ye, X., Li, Z., & Miao, J. (2013) · Journal of Peptide Science · doi:10.1002/psc.2484 · Cited by 14
RetractedWang, H.-Y., Trocmé, C., Stucky, A., Shah, S. M., Kvasic, J., Khan, A., Morain, P., Guignot, I., Bouguen, E., Deschet, K., et al. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0280-8 · Cited by 14
RetractedCommonalities in the genetics of Alzheimer’s disease and Parkinson’s disease
Grünblatt, E. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.12.1865 · Cited by 14
Nilsson, L. N. G., Gografe, S., Costa, D. A., Hughes, T., Dressler, D., & Potter, H. (2012) · Technology & Innovation · doi:10.3727/194982412x13462021398010 · Cited by 13
Do amyloid oligomers act as traps for misfolded proteins? A hypothesis
Gruschus, J. M. (2008) · Amyloid · doi:10.1080/13506120802193746 · Cited by 13
Xu, H., Yu, Z.-H., Ge, M.-J., Shen, J., Han, F., Pan, C., Chen, J., Zhu, X.-L., Hou, W.-Y., Hou, Y.-Q., et al. (2021) · Hormones and Behavior · doi:10.1016/j.yhbeh.2021.105040 · Cited by 11
Duszczyk, M., Kuszczyk, M. A., Guridi, M., Łazarewicz, J. W., & Sadowski, M. J. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2012.07.017 · Cited by 11
Self-citationProtein Interactome of Amyloid-β as a Therapeutic Target
Lazarev, V. F., Dutysheva, E. A., Kanunikov, I. E., Guzhova, I. V., & Margulis, B. A. (2023) · Pharmaceuticals · doi:10.3390/ph16020312 · Cited by 9
Opare, S. K. A., Petoyan, A., Mehrazma, B., & Rauk, A. (2015) · Canadian Journal of Chemistry · doi:10.1139/cjc-2015-0036 · Cited by 9
Shukla, D., Suryavanshi, A., Bharti, S. K., Asati, V., & Mahapatra, D. K. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266299847240328045737 · Cited by 10
Thomason, L. A. M., Stefanovic, B., & McLaurin, J. (2013) · European Journal of Neuroscience · doi:10.1111/ejn.12181 · Cited by 9
Endocytic mechanisms and drug discovery in neurodegenerative diseases
Zhang, M. (2008) · Frontiers in bioscience · doi:10.2741/3140 · Cited by 8
Armiento, V., Spanopoulou, A., & Kapurniotu, A. (2019) · Angewandte Chemie · doi:10.1002/ange.201906908 · Cited by 8
Lipid metabolism and Alzheimer's disease: pathways and possibilities
Saxena, U. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220902738720 · Cited by 9
New APOE-related therapeutic options for Alzheimer’s disease
Li, Z. (2019) · AIP conference proceedings · doi:10.1063/1.5085515 · Cited by 8
Apoe epsilon4 allele frequency in patients with dementia in different ethnic and geographic groups
Aslan, D., Ercan, F., Aybek, H., & Şahiner, T. (2010) · Cited by 7
Unraveling APOE4: The dual role in CNS and peripheral inflammation in Alzheimer's disease
Li, X., Li, Z., Chen, H., Guo, H., Ge, Y., Dong, F., Zhang, F., & Zhang, F. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115199 · Cited by 7
Targeting apolipoprotein E for treating Alzheimer’s disease
Bales, K. R., & Paul, S. M. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134366 · Cited by 7
Ge, T., Niu, A., Lv, Y., Chen, Y., Liu, Y., Lei, X., Li, Y., Ye, L., Liu, L., Li, Y., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114255 · Cited by 6
Pathogen infection in Alzheimer’s disease: pathophysiology and therapeutic strategies
Xiong, M., Yu, H., Tian, Y., Meng, L., & Zhang, Z. (2023) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2022.32 · Cited by 4
The Impact of Apolipoprotein E Allelic Variants on Alzheimer’s Disease
Serrano, E., Sanz, P. G., & Barrantes, F. J. (2021) · Springer eBooks · doi:10.1007/978-3-030-61721-9_29 · Cited by 4
Perspectives on the Role of APOE4 as a Therapeutic Target for Alzheimer’s Disease
Patel, K., Srivastava, S., Kushwah, S., & Mani, A. (2021) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-210027 · Cited by 4
Systemic AL amyloidosis with unusual cutaneous presentation unmasked by carotenoderma
Hůlková, H., Svojanovský, J., Ševela, K., Krusová, D., Hanuš, J., Vězda, P., Souček, M., Márová, I., Feit, J., Zambo, I. S., et al. (2013) · Amyloid · doi:10.3109/13506129.2013.851076 · Cited by 3
Donnelly, J. P., Schäfer, J.-H., Yoon, L., Massey, L. A., Ash, C. T., Gao, Z., Nugroho, K., Jäger, M., Pang, Z., O'Neill, R. T., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.042248 · Cited by 2
A Toxicogenic Interaction between Intracellular Amyloid-β and Apolipoprotein-E
Dey, A., Verma, A., Bhaskar, U., Sarkar, B., Kallianpur, M., Vishvakarma, V., Das, A. K., Garai, K., Mukherjee, O., Ishii, K., et al. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00048 · Cited by 3
Morelli, L., Perry, G. L., & Tagliavini, F. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/709613 · Cited by 2
Lipoproteins and Diseases of the Brain
Kim, K., & Palmore, G. T. R. (2017) · InTech eBooks · doi:10.5772/67053 · Cited by 2
Neuroprotection and Neuroregeneration in Alzheimer's Disease
Sugaya, K., Youdim, M. B. H., Nordberg, A. K., & Rao, K. S. J. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/864138 · Cited by 2
Binding of ApoE Isoforms to Aβ Peptides and Effects on Their Fibrillization
Friedemann, M., Noormägi, A., Jarvet, J., Gräslund, A., Wärmländer, S. K. T. S., Tõugu, V., & Palumaa, P. (2026) · ACS Omega · doi:10.1021/acsomega.5c12353 · Cited by 1
Lack of ApoE inhibits ADan amyloidosis in a mouse model of familial Danish dementia
Fernández, A., Gomez, M.-T., & Vidal, R. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102751 · Cited by 1
Current and Future Therapies for Alzheimer Disease
Chakrabarty, P., Das, P., & Golde, T. E. (2010) · Wiley eBooks · doi:10.1002/9780470572702.ch34 · Cited by 1
Alzheimer Disease, Genetics of
Kehoe, P. G. (2008) · Wiley eBooks · doi:10.1002/9780470015902.a0020228 · Cited by 1
The Role of Apolipoprotein E Concentration and Isoform in Amyloid-beta Metabolism In Vivo
Castellano, J. M. (2011) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7416v3s
Role of the 39-kDa receptor-associated protein (RAP) in Alzheimer's disease
Hoang, T. (2012) · UTAS Research Repository · doi:10.25959/23206328
Endosomes élargis et cholestérol : De la trisomie 21 à la maladie d'Alzheimer
Cossec, J. (2009) · OpenGrey (Institut de l'Information Scientifique et Technique)
Preliminary assay of β-amyloid binding elements in heart-beneficial recipe
Cheng, M. (2008) · Journal of Chinese Integrative Medicine · doi:10.3736/jcim20080113
Alzheimer’s Disease Therapeutics Targeting Apolipoprotein E
Liao, F., & Holtzman, D. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00010-1
Albrecht, M. A., & Foster, J. K. (2016) · Springer eBooks · doi:10.1007/978-1-4939-3777-6_7
AXL receptor tyrosine kinase regulates Apolipoprotein E expression
Zhao, W. (2019) · cIRcle (University of British Columbia) · doi:10.14288/1.0372324
Jamolovna, R. M. (2020) · International Engineering Journal For Research & Development · doi:10.17605/osf.io/zfjw9
SPECIFIC CLINICAL COURSE OF ACUTE CORONARY SYNDROME IN YOUNG PEOPLE
Abbosovich, A. L. (2020) · International Engineering Journal For Research & Development · doi:10.17605/osf.io/tjxpy
In vivo study demonstrates potential of blocking apoE/Aβ in Alzheimer's disease
(2007) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0416
Donnelly, J. P., Schäfer, J.-H., Yoon, L., Massey, L. A., Ash, C. T., Gao, Z., Nugroho, K., Jäger, M., Pang, Z., O'Neill, R. T., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.09.704431
Etude préclinique et clinique de la phase précoce de la maladie d'Alzheimer
Epelbaum, S. (2015) · theses.fr (ABES) · doi:10.70675/ea81e5c2z5032z4474z9f96z59f62125a629
Hanbouch, L. (2017) · theses.fr (ABES) · doi:10.70675/c4d2c894zf69dz4ae4z9ab1zf4135d0efa12
Gillet, J.-N. (2026) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2026.2671163
Apoprotein E: Structural insights functionality and genetic variability
Tewari, S., & Ranade, S. D. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40563-1.00008-9
Emerging therapeutic strategies to target APOE4 in Alzheimer's disease
Jiang, W. I., 王冰莹, & Ma, D. K. (2026) · FEBS Journal · doi:10.1111/febs.70759
Metadata
- Authors
- Sadowski, M. J., Pankiewicz, J., Scholtzova, H., Mehta, P. D., Prelli, F., Quartermain, D., & Wisniewski, T.
- Affiliations
- *Departments of Neurology,
- New York State Institute for Basic Research in Developmental Disabilities, 1050 Forest Hill Road, Staten Island, NY 10314
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2006-12-05
- Volume
- 103
- Issue
- 49
- Pages
- 18787-18792
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC1654132
- OpenAlex
- W2004069543
- Cited by
- 167
- References
- 29
- Citations by year
- 2026: 6 · 2025: 3 · 2024: 5 · 2023: 3 · 2022: 3 · 2021: 7 · 2020: 8 · 2019: 8 · 2018: 6 · 2017: 7 · 2016: 5 · 2015: 5 · 2014: 16 · 2013: 13 · 2012: 16
- FWCI
- 8.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (AG15408, R01AG015408, AG 20747, P30AG008051, R01AG020245, K08AG020747)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta, apolipoprotein E, synthetic peptides, amyloid-beta clearance, cerebral amyloid angiopathy, amyloid plaques, amyloid-beta oligomers, memory impairment, transgenic mouse model, blood-brain barrier permeability, therapeutic target
- MeSH terms
- Alzheimer Disease, Animals, Apolipoproteins E, Binding, Competitive, Female, Mice, Transgenic, Peptide Fragments, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
